Patents by Inventor Steven H. Olson

Steven H. Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazole agonists of the APJ receptor
    Patent number: 9656997
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: May 23, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • Intermediates for preparing triazole agonists of the APJ receptor
    Patent number: 9656998
    Abstract: Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: May 23, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Xiaodong Wang, Kevin Yang, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd
  • Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
    Patent number: 9593129
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 14, 2017
    Assignee: Amgen, Inc.
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Jr., Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua Ma, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Triazole agonists of the APJ receptor
    Patent number: 9573936
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: February 21, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170042872
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 16, 2017
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua Ma, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. Judd, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170044131
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 16, 2017
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170042871
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 16, 2017
    Inventors: Ning Chen, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170042897
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 16, 2017
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170037026
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 9, 2017
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20170035744
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • TRIAZOLE AGONISTS OF THE APJ RECEPTOR
    Publication number: 20160340336
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: May 18, 2016
    Publication date: November 24, 2016
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
    Patent number: 9376425
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: June 28, 2016
    Assignee: Amgen, Inc.
    Inventors: Michael D. Bartberger, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, John Eksterowicz, Brian M. Fox, Jiasheng Fu, Ana Gonzalez Buenrostro, Felix Gonzalez Lopez De Turiso, Darin J. Gustin, Julie A. Heath, Michael G. Johnson, Frank Kayser, David John Kopecky, Yihong Li, Zhihong Li, Zhihua Ma, Joel McIntosh, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yosup Rew, Philip M. Roveto, Michael J. Schmitt, Daqing Sun, Xiaodong Wang, Malgorzata Wanska, Christine Weathers, Xuelei Yan
  • Pyrazole amide derivative
    Patent number: 9365522
    Abstract: The present invention relates to a novel compound having a function of inhibiting ROR? activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: June 14, 2016
    Assignees: AMGEN INC., TEIJIN PHARMA LIMITED
    Inventors: Hilary Plake Beck, Shon Keith Booker, Howard Bregman, Victor J. Cee, Nagasree Chakka, Timothy D. Cushing, Oleg Epstein, Brian M. Fox, Stephanie Geuns-Meyer, Xiaolin Hao, Kenta Hibiya, Jun Hirata, Zihao Hua, Jason Human, Shinji Kakuda, Patricia Lopez, Ryota Nakajima, Kazuhisa Okada, Steven H. Olson, Hiroyuki Oono, Lewis D. Pennington, Kosuke Sasaki, Keiko Shimada, Youngsook Shin, Ryan D. White, Ryan P. Wurz, Shuyan Yi, Xiao Mei Zheng
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20160137667
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: January 27, 2016
    Publication date: May 19, 2016
    Applicant: AMGEN INC.
    Inventors: Michael D. BARTBERGER, Ana GONZALEZ BUENROSTRO, Hilary Plake BECK, Xiaoqi CHEN, Richard Victor CONNORS, Jeffrey DEIGNAN, Jason A. DUQUETTE, John EKSTEROWICZ, Benjamin FISHER, Brian M. FOX, Jiasheng FU, Zice FU, Felix GONZALEZ LOPEZ DE TURISO, Michael W. GRIBBLE, JR., Darin J. GUSTIN, Julie A. HEATH, Xin HUANG, XianYun JIAO, Michael G. JOHNSON, Frank KAYSER, David John KOPECKY, SuJen LAI, Yihong LI, Zhihong LI, Jiwen LIU, Jonathan D. LOW, Brian S. LUCAS, Zhihua MA, Lawrence R. MCGEE, Joel MCINTOSH, Dustin L. MCMINN, Julio C. MEDINA, Jeffrey Thomas MIHALIC, Steven H. OLSON, Yosup REW, Phillip M. ROVETO, Daqing SUN, Xiaodong WANG, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU
  • Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
    Patent number: 9296736
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: March 29, 2016
    Assignee: Amgen INC.
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua Ma, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20160039774
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).
    Type: Application
    Filed: March 13, 2014
    Publication date: February 11, 2016
    Applicant: AMGEN INC.
    Inventors: Ana GONZALEZ BUENROSTRO, Yihong LI, Julio C. MEDINA, Steven H. OLSON
  • CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20160002185
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: February 18, 2014
    Publication date: January 7, 2016
    Applicant: AMGEN INC.
    Inventors: Michael D. BARTBERGER, Hilary Plake BECK, Michael R. DEGRAFFENREID, Brian M. FOX, Felix GONZALEZ LOPEZ DE TURISO, Lisa D. JULIAN, Frank KAYSER, Julio C. MEDINA, Steven H. OLSON, Yosup REW, Philip M. ROVETO, Daqing SUN, Xuelei YAN
  • Pyrazole Amide Derivative
    Publication number: 20150266824
    Abstract: The present invention relates to a novel compound having a function of inhibiting ROR? activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
    Type: Application
    Filed: February 27, 2015
    Publication date: September 24, 2015
    Inventors: Hilary Plake Beck, Shon Keith Booker, Howard Bregman, Victor J. Cee, Nagasree Chakka, Timothy D. Cushing, Oleg Epstein, Brian M. Fox, Stephanie Geuns-Meyer, Xiaolin Hao, Kenta Hibiya, Jun Kirata, Zihao Hua, Jason Human, Shinji Kakuda, Patricia Lopez, Ryota Nakajima, Kazuhisa Okada, Steven H. Olson, Hiroyuki Oono, Lewis D. Pennington, Kosuke Sasaki, Keiko Shimada, Youngsook Shin, Ryan D. White, Ryan P. Wurz, Shuyan Yi, Xiao Mei Zheng
  • PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20140315895
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: June 26, 2014
    Publication date: October 23, 2014
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez de Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel Mcintosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20140235629
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: September 26, 2012
    Publication date: August 21, 2014
    Inventors: Michael D. Bartberger, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, John Eksterowicz, Brian M. Fox, Jiasheng Fu, Ana Gonzalez Buenrostro, Felix Gonzalez Lopez De Turiso, Darin J. Gustin, Julie A. Heath, Michael G. Johnson, Frank Kayser, David John Kopecky, Yihong Li, Zhihong Li, Zhihua Ma, Joel Micintosh, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yosup Rew, Philip M. Roveto, Michael J. Schmitt, Daqing Sun, Xiaodong Wang, Malgorzata Wanska, Christine Weathers, Xuelei Yan